These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 21868753

  • 1. Combined tadalafil and α-blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: a multicenter, prospective study.
    Lee JY, Park SY, Jeong TY, Moon HS, Kim YT, Yoo TK, Choi HY, Park HY, Lee SW.
    J Androl; 2012; 33(3):397-403. PubMed ID: 21868753
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of the simultaneous administration of mirodenafil and an α-blocker in men with BPH-LUTS: a multicenter open-label prospective study.
    Bang WJ, Oh CY, Yoo C, Cho JS, Yang DY, Lee DH, Lee SH, Chung BH.
    Int J Impot Res; 2013; 25(4):149-54. PubMed ID: 23303333
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H, Kim ED, Casabé AR, Mirone V, Secrest RJ, Xu L, Sundin DP, Viktrup L, LVHJ study team.
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [Abstract] [Full Text] [Related]

  • 4. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV, Mete UK, Mandal AK, Singh SK.
    J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study.
    Lee JY, Cho SY, Oh CY, Ha US, Lee SH, Park SY, Moon HS, Lee SW.
    Int J Impot Res; 2011 Jan; 23(6):249-56. PubMed ID: 21814227
    [Abstract] [Full Text] [Related]

  • 6. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G, Broderick G, Roehrborn CG, Xu L, Wong D, Viktrup L.
    BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
    [Abstract] [Full Text] [Related]

  • 7. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
    Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, Wong DG, Secrest RJ.
    J Sex Med; 2012 Jan; 9(1):271-81. PubMed ID: 21981682
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report.
    Liguori G, Trombetta C, De Giorgi G, Pomara G, Maio G, Vecchio D, Ocello G, Ollandini G, Bucci S, Belgrano E.
    J Sex Med; 2009 Feb; 6(2):544-52. PubMed ID: 19138360
    [Abstract] [Full Text] [Related]

  • 9. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
    Miller MS.
    Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
    [Abstract] [Full Text] [Related]

  • 10. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study.
    Giuliano F, Oelke M, Jungwirth A, Hatzimouratidis K, Watts S, Cox D, Viktrup L.
    J Sex Med; 2013 Mar; 10(3):857-65. PubMed ID: 23346990
    [Abstract] [Full Text] [Related]

  • 11. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L.
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [Abstract] [Full Text] [Related]

  • 12. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study.
    Bechara A, Romano S, Casabé A, Haime S, Dedola P, Hernández C, Rey H.
    J Sex Med; 2008 Sep; 5(9):2170-8. PubMed ID: 18638006
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis.
    Dong Y, Hao L, Shi Z, Wang G, Zhang Z, Han C.
    Urol Int; 2013 Sep; 91(1):10-8. PubMed ID: 23816815
    [Abstract] [Full Text] [Related]

  • 14. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.
    Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L.
    Urology; 2010 Jun; 75(6):1452-8. PubMed ID: 20163842
    [Abstract] [Full Text] [Related]

  • 15. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment.
    Roehrborn CG, Kaminetsky JC, Auerbach SM, Montelongo RM, Elion-Mboussa A, Viktrup L.
    BJU Int; 2010 Feb; 105(4):502-7. PubMed ID: 19732051
    [Abstract] [Full Text] [Related]

  • 16. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
    Brock GB, McVary KT, Roehrborn CG, Watts S, Ni X, Viktrup L, Wong DG, Donatucci C.
    J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
    [Abstract] [Full Text] [Related]

  • 17. Tadalafil - a therapeutic option in the management of BPH-LUTS.
    Carson CC, Rosenberg M, Kissel J, Wong DG.
    Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
    [Abstract] [Full Text] [Related]

  • 18. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
    Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L.
    Eur Urol; 2012 May; 61(5):917-25. PubMed ID: 22297243
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.
    Porst H, Oelke M, Goldfischer ER, Cox D, Watts S, Dey D, Viktrup L.
    Urology; 2013 Sep; 82(3):667-73. PubMed ID: 23876588
    [Abstract] [Full Text] [Related]

  • 20. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
    Glina S, Roehrborn CG, Esen A, Plekhanov A, Sorsaburu S, Henneges C, Büttner H, Viktrup L.
    J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.